New drug delivery methods tested for tough breast cancer
NCT ID NCT07560475
First seen May 08, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study is for people with HER2-positive advanced breast cancer. It tests a drug called SHR-A1811 given in different ways (like injection or infusion) to see which works best and is safest. About 60 adults who have had up to 2 prior treatments will take part. The goal is to shrink tumors and delay cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Insititute and Hospital
Tianjin, 300060, China
Conditions
Explore the condition pages connected to this study.